Crohn's Disease Clinical Research Trials

Birmingham : University of Alabama at Birmingham

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Birmingham :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Mobile : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Little Rock : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Phoenix : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Scottsdale : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Scottsdale : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tucson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tucson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tucson : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Jonesboro : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Little Rock :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Little Rock : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Little Rock : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Little Rock : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Anaheim : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Francisco : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Glendale : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

La Jolla : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

La Jolla : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Los Angeles : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oakland : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Orange : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Orange : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orange : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Redlands : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Redwood City : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Sacramento : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

San Carlos : Digestive Care Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Carlos :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

San Diego : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Diego : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Diego :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

San Diego : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Diego : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

San Francisco : University of California at San Francisco

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Francisco : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Francisco : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Francisco : University of California, San Francisco Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

San Francisco : University of California, San Francisco Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

San Francisco : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

SanDiego : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Santa Monica : Southern California Medical Gastroenterology Group

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Stanford : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Whittier : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Denver : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Denver : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Denver : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Lafayette : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Lakewood : Rocky Mountain Gastroenterology Associates

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lakewood : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lakewood : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lakewood : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lakewood : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Littleton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Littleton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Littleton : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Littleton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Lone Tree :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Thornton : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Thornton : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Bridgeport : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bridgeport : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Glastonbury : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hartford : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Haven : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New Haven : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Clearwater : Clinical Research of West Florida, Inc.

Are you interested in taking part in a New Research Study of an Investigational drug for CROHN'S DISEASE?

Clearwater : Clinical Research of West Florida, Inc.

Crohn's disease research study

Gainesville : University of Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Gainesville : University of Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clearwater : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Clearwater : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Clearwater : Clinical Research of West Florida Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Clearwater : Clinical Research of West Florida Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crystal River : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Gainesville : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Gainesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Gainesville : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gainesville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Gainesville : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Gainsville : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Inverness : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Inverness : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jacksonville : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Jacksonville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jacksonville : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Largo : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Maitland : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Miami : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Miami : Jackson Memorial Hospital

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

Miami : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Miami : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Miami : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Naples : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Naples : Gastroenterology Group of Naples

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Naples : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Naples : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

New Port Richey : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Orlando : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orlando : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Port Orange : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Sanford : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sanford : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Trinity : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Weston : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Weston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Winter Park : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Winter Park : Shafran Gastroenterology Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Winter Park : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Winter Park : Shafran Gastroenterology Center

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Winter Park : Shafran Gastroenterology Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gasteroenterology Center

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Zephyrhills : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Atlanta :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Atlanta : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Atlanta : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Atlanta : Atlanta Gastroenterology Associates

Optimizing Cimzia in Crohn's Patients

Atlanta : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Atlanta : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Atlanta : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Decatur : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Decatur :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Decatur : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Decatur : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Macon : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Macon : Gastroenterology Associates of Central Georgia

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Macon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Macon : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Macon : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Marietta : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Marietta : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Boise : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chicago : Rush University Medical Center - Treatment Research Center

Dysbiosis in inflammatory bowel disease.

Chicago : University of Chicago Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : Rush University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : University of Chicago Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chicago : Rush University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chicago : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chicago : University of Chicago Hospital Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chicago : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Chicago : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chicago : University of Chicago Medical Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chicago : University of Chicago Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chicago : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chicago : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Evanston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Anderson : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Indianapolis : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Indianapolis : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Indianapolis : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Clive : Iowa Digestive Disease Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Digestive & Liver Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Iowa Digestive Disease Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clive : Digestive & Liver Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clive : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Clive : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Iowa City : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kansas City : University Of Kansas

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : University Of Kansas

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pratt : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Topeka : Cotton-O'Neil Clinical Research Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Topeka : Cotton-O'Neil Clinical Research Center Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Lexington : University of Kentucky Chandler Medical Center

Does your Crohn's require surgery?

Lexington : University of Kentucky Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lexington : University of Kentucky Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Crestview Hills : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lexington : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lexington : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lexington : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Lexington : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lexington : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lexington : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Louisville : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Louisville : University of Louisville School of Medicine

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Baton Rouge : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hammond : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hammond : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hammond : Gastroenterology Research Of New Orleans

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Hammond : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Monroe : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Monroe : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

New Orleans : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Portland : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research

Ulcerative Colitis and Crohn’s Disease (IBD) Research Study

Prince Frederick : Shah Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Prince Frederick : Shah Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Annapolis : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Annapolis : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Baltimore : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Baltimore : University of Maryland, Baltimore Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Baltimore : University of Maryland, Baltimore Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Baltimore : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bethesda : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chevy Chase : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chevy Chase : Metropolitan Gastroenterology Group. PC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chevy Chase :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chevy Chase : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chevy Chase : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chevy Chase : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chevy Chase : Chevy Chase Clinical Research Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Chevy Chase : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chevy Chase : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Hollywood : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Towson : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Towson : Endoscopic Microsurgery Associates PA

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Towson : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Boston : Massachusetts General Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boston : Massachusetts General Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boston : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Boston : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Boston : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Boston : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Brockton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Fall River : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Worcester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Worcester : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Dearborn : The Center for Clinical Studies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dearborn : The Center for Clinical Studies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Ann Arbor : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Ann Arbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ann Arbor : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ann Arbor : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chesterfield : Clinical Research Institute of Michigan

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chesterfield : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chesterfield : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chesterfield : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Detroit : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Novi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Troy : Center for Digestive Health

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Troy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Troy : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Troy : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Troy : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Troy : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Utica : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Ypsilanti : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Minneapolis : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Plymouth : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Plymouth : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rochester : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Rochester : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Rochester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Rochester : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Rochester : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Saint Paul : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

St. Paul : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

St. Paul : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Tupelo : Digestive Health Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tupelo : Digestive Health Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Ocean Springs : Digestive Health Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Ocean Springs : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kansas City : Truman Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : Truman Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lees Summit : Midwest Center for Clinical Research

Study of an investigational medication from Bristol Myers Squibb in patients with moderate to severe active Crohn's Disease.

Lees Summit : Midwest Center for Clinical Research

Study of an investigational medication from GlaskoSmithKline to evaluate two oral doses of GSK1605786 (GSK786) as compared to placebo in the induction of clinical response over a 12-week treatment period in subjects with moderately to severely active Crohn’s disease.

Lees Summit : Midwest Center for Clinical Research

Study of Stelara, an investigational medication from Centocor/Johnson&Johnson to evaluate the safety and efficacy of Ustekinumab (Stelara) in patients with moderately to severely active Crohn's Disease.

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Columbia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Kansas City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kansas City : The Children's Mercy Hospital

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Lees Summit : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lees Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Lees Summit : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lee's Summit : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lee'S Summit : Midwest Center For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Mexico :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Mexico : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mexico : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Saint Louis :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Saint Louis : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

St Louis : St Louis Center for Clinical Studies Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

St. Louis : St. Louis Center for Clinical Studies Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : Saint Louis Center for Clinical Research Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Boys Town : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Las Vegas : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lebanon : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lebanon : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lebanon : Dartmouth Hitchcock Medical Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Lebanon : Dartmouth HItchcock Medical Center Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Berlin : Research Site Updated

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Egg Harbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Egg Harbor : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Marlton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Marlton : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mays Landing : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Mays Landing : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Mays Landing : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Morristown :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Morristown : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Morristown : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Morristown : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Morristown : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Poughkeepsie : Gastroenterology Associates

A Non-Interventional Long-term Post-Marketing Registry of Patients Treate with Certolizumab Pegol (Cimzia®) for Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Albany : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Brooklyn : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Brooklyn : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Buffalo : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Great Neck : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Great Neck : Long Island Clinical Research Associates, LLP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Great Neck : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Great Neck : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Great Neck : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Great Neck : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Great Neck : Long Island Clinical Research Assoc., Llp

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Great Neck : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Great Neck : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Mineola : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Hyde Park : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New York : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

New York :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

New York : Mount Sinai School of Medicine Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York : Mount Sinai School of Medicine

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Poughkeepsie : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Poughkeepsie : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Poughkeepsie : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Poughkeepsie : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Rochester : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Stony Brook : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Charlotte : PMG Research of Charlotte

Crohn's Disease

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Raleigh : Wake Research Associates

Crohn’s Disease Research Study

Raleigh : Wake Research Associates

Do you suffer from Crohn’s Disease?

Raleigh : Wake Research Associates

Study of Crohn's Disease Now Enrolling

Raleigh : Wake Research Associates

Treating your Crohn's disease doesn't have to be a solo act.

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boone : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chapel Hill : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chapel Hill : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chapel Hill : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chapel Hill : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlotte : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Charlotte : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Charlotte : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Charlotte : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Durham : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Durham : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Durham : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Durham : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Elkin :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Huntersville : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Huntersville : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Raleigh : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Raleigh : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Raleigh : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Raleigh : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Raleigh : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Beachwood : Gastroenterology Associates of Cleveland, Inc.

Research trial now enrolling for Humira ® for Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Beavercreek :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cincinnati : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Cincinnati : Consultants for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Ohio Gastroenterology and Liver

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Cincinnati : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cincinnati : Consultants For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Columbus : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Dayton : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Dayton : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Mentor : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Mentor : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Tulsa : Options Health Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tulsa : Options Health Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Oklahoma City : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oklahoma City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oklahoma City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Oklahoma City : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City : Research Site Updated

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Oklahoma City : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oklahoma City, : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tulsa : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tulsa : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tulsa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Portland : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Portland : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Portland : Oregon Health & Science University

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Portland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Springfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Danville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Duncansville : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

King of Prussia : Omnicare Clinical Research, Inc.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Lancaster : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Philadelphia : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Pittsburg : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburg : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pittsburgh : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Pittsburgh : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburgh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pittsburgh : Children's Hospital of Pittsburgh of UPMC

Autologous Stem Cell Transplantation for Crohn's Disease

Pittsburgh : University of Pittsburgh Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

East Providence : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

East Providence : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Providence : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Charleston : Medical University Of SC CAR

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charleston : Medical University Of SC CAR

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Greenville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

North Charleston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Germantown : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Germantown : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Germantown : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Germantown : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Germantown : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Germantown : Gastroenterology Center of the Midsouth Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Germantown : Gastroenterology Center of the Midsouth, PC Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Germantown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Knoxville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Memphis : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Nashville : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nashville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Nashville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nashville : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Nashville : Vanderbilt University Medical Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Nashville : Vanderbilt University Medical Center Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Nashville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Austin : Austin Gastroenterology, PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Austin : Austin Gastroenterology, PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Alamo Medical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Alamo Medical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Austin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Austin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Austin : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Austin : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Austin : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Dallas : Baylor University Medical Center Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Dallas : Baylor University Medical Center Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dallas : Dallas VA Medical Center

Exacerbating Factors in Inflammatory Bowel Disease

Dallas : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Fort Worth : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Grapevine : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Grapevine : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Grapevine : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Houston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Houston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Houston : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pasadena : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pasadena : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Plano : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Antonio : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Antonio : Gastroenterology Research Of San Antonio

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

San Antonio : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Sugar Land : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Tyler : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tyler : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Tyler : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Ogden : GSK Investigational Site

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ogden : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Salt Lake City : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Salt Lake City : University of Utah

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Salt Lake City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Burlington : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Burlington : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville : Charlottesville Medical Research

Crohn’s Disease?

Charlottesville : Charlottesville Medical Research

Do you have Crohn’s?

Charlottesville : University of Virginia Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlottesville : University of Virginia Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Virginia Beach : Gastroenterology, Ltd.

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease

Charlottesville : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Charlottesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Charlottesville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chesapeake :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Chesapeake : Pfizer Investigational Site

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Fairfax : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Norfolk :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Norfolk : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Norfolk : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Richmond : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Richmond : McGuire Research Institute Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Richmond : McGuire Research Institute Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Richmond : Research Site Updated

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Virginia Beach :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Virginia Beach : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Seattle : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Seattle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Seattle : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seattle : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Seattle : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seattle : University of Washington Medical Center

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Seattle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seattle : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Tacoma : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Morgantown : United BioSource Corporation

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Madison : Pharmaseek, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Madison : Pharmaseek, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Madison : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Madison :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Madison : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madison : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Milwaukee : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Wauwatosa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Wauwatosa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Adelaide : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Adelaide : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Adelaide :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Adelaide : Royal Adelaide Hospital Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Adelaide : Royal Adelaide Hospital Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Adelaide : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Adelaide : Research Site Updated

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Adelaide : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Adelaide : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bankstown : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bankstown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brisbane : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brisbane : QPharm

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Central Queensland M C : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Fitzroy : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fitzroy : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fremantle : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Fremantle : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Garran : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hersten : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hersten : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Herston : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Herston : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Kurralta Park : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Malvern : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Melbourne : Royal Melbourne Hospital Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Melbourne : Royal Melbourne Hospital Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Melbourne : Center for Clinical Studies

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Nambour : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Parkville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Parkville : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Prahran : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Prahran : Research Site Updated

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Prahran : Research Site Updated

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Graz : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Salzburg : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Stolzalpe N/A : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Vienna : Site Reference ID/Investigator# 38145

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Wien : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Wien : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Antwerp : UZ Antwerpen

Switching From Adalimumab to Infliximab

Belgium : Belgium

A Study of TRK-170 for the Treatment of Crohn's Disease

Bonheiden : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Bonheiden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bonheiden : Site Reference ID/Investigator# 38147

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bonheiden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brussel : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brussel : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Brussels : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brussels : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Brussels : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Crohn's Disease Volunteers Who Failed Or Did Not Tolerate Anti-TNFs

Brussels : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Edegem : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edegem : Site Reference ID/Investigator# 43966

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Gent : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Gent : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Gent : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ghent : University Hospital Ghent

Switching From Adalimumab to Infliximab

Hasselt : Virga Jesse hospital

Switching From Adalimumab to Infliximab

Kortrijk : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kortrijk : AZ Groeninge

Switching From Adalimumab to Infliximab

Leuven : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Leuven : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Leuven :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Leuven : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Leuven : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Leuven : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Leuven :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Leuven : UZ Leuven

Switching From Adalimumab to Infliximab

Liege : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oostende : AZ Damiaan

Switching From Adalimumab to Infliximab

Ottignies : Clinique Saint-Pierre

Switching From Adalimumab to Infliximab

Roeselare : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Roeselare : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Roeselare : Site Reference ID/Investigator# 38146

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Roeselare : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Roeselare : Heilig Hartziekenhuis Roeselare

Switching From Adalimumab to Infliximab

Curitiba : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Brandon : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brandon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Brandon : Updated

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Calgary : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Calgary : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Calgary : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Calgary : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Calgary : Site Reference ID/Investigator# 38156

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Calgary : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Calgary : Division of Gastroenterology

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Edmonton : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Edmonton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edmonton :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Edmonton : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edmonton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Guelph : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Halifax : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Halifax : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Halifax : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Halifax : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hamilton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamilton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kingston : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kingston : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Levis : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

London : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

London : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

London : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

London : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

London :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Montreal : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Montreal : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Montreal : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Montreal : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Ottawa : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ottawa : Investigational Site 5

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Quebec : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Quebec : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Quebec : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Saskatoon :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Toronto : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Toronto : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Toronto : Investigational Site 1

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Toronto : Investigational Site 4

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Vancouver : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vancouver : Site Reference ID/Investigator# 45502

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vancouver : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vancouver : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Vancouver : Investigational Site 3

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

Vaughan : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Vaughan : Site Reference ID/Investigator# 38155

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vaughan : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Winnipeg : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Winnipeg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Winnipeg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hradec Kralove : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hradec Kralove : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hradec Kralove : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hradec Kralove 12 : Site Reference ID/Investigator# 38159

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Litomerice : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Olomouc : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Olomouc : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Olomouc : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ostrava - Vitkovice : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ostrava - Vitkovice : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Praha 10 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 4 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 4 : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 4 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 7 : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Praha 7 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 7 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 9 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aalborg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aalborg : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aarhus : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aarhus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus C : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Herlev : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hilleroed : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hvidovre : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hvidovre : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hvidovre : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hvidovre : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Koebenhavn : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Odense : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amiens : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Amiens : Site Reference ID/Investigator# 38164

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amiens cedex 1 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amiens Cedex 1 : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Bordeaux : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Caen : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Clichy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Clichy cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

France : France

A Study of TRK-170 for the Treatment of Crohn's Disease

Grenoble : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lille : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lille Cedex : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lille cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lille Cedex : Site Reference ID/Investigator# 38163

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lille cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Marseille : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nantes : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nice : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nice : Site Reference ID/Investigator# 42839

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Nice cedex 3 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nice cedex 3 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Paris : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

Paris :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Paris Cedex 12 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pessac : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pessac cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pessac Cedex : Site Reference ID/Investigator# 42818

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Pessac cedex : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Pessac cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Pessac N/A : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rouen : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rouen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vandoeuvre Les Nancy : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Vandoeuvre Les Nancy : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vandoeuvre Les Nancy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Berlin : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Berlin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Berlin : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Berlin : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Berlin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Dachau : Site Reference ID/Investigator# 38172

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Erlangen : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Erlangen : Department of Medicine I, University of Erlangen-Nuremberg

Endomicroscopy in IBD Patients

Erlangen : Medizinische Klinik I, University Hospital Erlangen

Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut

Frankfurt am Main : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Frankfurt am Main : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Halle :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Hamburg : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamburg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamburg : Site Reference ID/Investigator# 38169

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Hamburg : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hannover : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hannover : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hannover : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hannover : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Heidelberg : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Herne : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kiel : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kiel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kiel : Site Reference ID/Investigator# 38170

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Leipzig : Site Reference ID/Investigator# 44042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lÿneburg : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Magdeburg : Site Reference ID/Investigator# 38168

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Mannheim : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Minden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Minden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Minden : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Minden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Muenster : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

München : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Münster : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Regensburg : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Regensburg : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Tübingen : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Ulm : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ulm : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ulm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Athens : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Bekescsaba : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Békéscsaba : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Budapest : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Budapest : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Debrecen : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Gyor :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Pecs N/A : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Szekszard : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekszard :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Szekszárd : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Reykjavik :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Dublin 4 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ashkelon : Barzilai Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Rambam Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Bnai Zion Hospital

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Israel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Jerusalem : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Jerusalem : Hadassah Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Jerusalem : Shaarei Tzedek Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Kfar Saba : Meir Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Kfar Saba :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Petach Tikva : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Petah Tikva : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rehovot : Kaplan Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Aviv : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Tel Aviv :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Tel Aviv : Tel Aviv Sourasky Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Hashomer : Sheba Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Zerifin : Assaf Harofeh

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Roma : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Rome : Site Reference ID/Investigator# 38178

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rozzano : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rozzano : Site Reference ID/Investigator# 38177

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Aichi : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aichi : Site Ref # / Investigator 48682 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48683 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48684 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48685 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48692 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48693 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48694 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 48695 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49010 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49015 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49018 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49019 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 65140 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 60244 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 60256 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 60508 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55865 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55871 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55877 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55880 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49023 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49026 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49011 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49013 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 49016 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55307 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55608 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55615 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55616 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 65148 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 65107 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 60513 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55710 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55800 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55869 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55870 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55872 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55873 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55874 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55875 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aichi : Site Ref # / Investigator 55876 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aizuwakamatsu : Site Ref # / Investigator 48652 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 48650 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55909 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55905 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55906 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55907 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55660 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 55705 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Akita : Site Ref # / Investigator 60376 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Anjo : Site Ref # / Investigator 55617 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55584 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55585 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55311 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 48797 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55899 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55900 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 60363 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 60509 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 65111 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 65144 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55897 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55898 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Aomori : Site Ref # / Investigator 55902 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chiba : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chiba : Site Ref # / Investigator 48668 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48671 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48672 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 49000 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 49001 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 49002 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 49006 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55701 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55831 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55841 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55820 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55822 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55823 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55824 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55825 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 65138 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 65115 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 60510 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55788 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55796 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55821 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55826 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55827 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55832 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 60257 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 60378 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 65116 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 65117 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 55647 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48666 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48667 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48669 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Chiba : Site Ref # / Investigator 48670 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 55583 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 55313 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 49075 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 48758 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 65155 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 56024 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 56026 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 56044 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 60553 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 49071 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 49076 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ehime : Site Ref # / Investigator 48757 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 55793 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 55771 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 60397 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 48744 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 55312 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukui : Site Ref # / Investigator 55190 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fukuoka : Site Ref # / Investigator 49074 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49077 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49078 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 55618 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48760 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48761 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48762 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48763 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48764 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60519 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 65146 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 65130 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60558 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56039 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56043 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56052 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60530 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60535 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60537 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 60426 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 65131 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 65151 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56036 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56037 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56038 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56040 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56041 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56042 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 56048 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48784 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48765 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48766 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48767 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 48768 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49079 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49080 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49081 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49083 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49084 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49069 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka : Site Ref # / Investigator 49086 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukuoka-shi : Site Ref # / Investigator 55305 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55597 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55316 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55163 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 60259 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 60563 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55798 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55603 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55946 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55947 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55950 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55951 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55948 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55949 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 55720 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 60386 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 60248 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima : Site Ref # / Investigator 48654 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Fukushima-city : Site Ref # / Investigator 48984 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 49020 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 49022 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55621 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55622 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55623 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55624 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55626 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55627 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55628 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55629 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 48698 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60423 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60246 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60368 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60262 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60412 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 48696 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 48697 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55620 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55625 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 55319 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60258 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60387 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60559 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gifu : Site Ref # / Investigator 60556 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 65105 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55964 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55965 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55966 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55967 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 48657 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 60380 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 60372 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55968 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55697 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 55185 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Gunma : Site Ref # / Investigator 48998 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 49063 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55581 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55694 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55789 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56000 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56001 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56002 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56004 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56005 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56006 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56008 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55997 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56010 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 60401 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 60398 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 60560 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 49068 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55164 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55601 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 55574 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 48751 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 49064 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56003 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56007 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 56014 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hiroshima : Site Ref # / Investigator 60554 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hokkaido : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hokkaido : Site Ref # / Investigator 60552 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 60557 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 60540 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55884 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55885 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55886 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55888 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55894 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55797 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55879 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48787 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48788 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48790 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48791 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48792 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48794 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48796 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48642 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48643 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48644 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48648 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 47382 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48645 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48646 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48789 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48793 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 48795 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55315 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 65109 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 65110 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55791 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55868 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55878 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55887 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55889 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55890 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55891 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55892 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55893 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55895 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55896 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55785 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hokkaido : Site Ref # / Investigator 55713 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hyogo : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hyogo : Site Ref # / Investigator 60528 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60388 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60389 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60402 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60251 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55803 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55804 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55742 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55743 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55749 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55752 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55754 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55756 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48707 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48709 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48710 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48711 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48712 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48713 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 49046 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48785 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48786 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55599 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55172 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55573 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55744 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55745 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55746 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55747 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55748 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55750 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55751 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55753 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55755 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55757 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55758 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55759 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55691 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55692 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55703 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 65124 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 65143 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60523 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60531 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60375 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60364 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 60224 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55593 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55156 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 55157 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 49047 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 49042 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Hyogo : Site Ref # / Investigator 48708 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 48656 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 48994 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 49008 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55588 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55693 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55958 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55959 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55596 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55605 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 48991 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 48995 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55704 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55955 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55956 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 55957 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 60362 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 60524 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ibaraki : Site Ref # / Investigator 60407 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 65125 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 65126 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55763 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55765 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55767 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55768 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55769 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55770 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55853 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 49052 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55600 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55194 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55764 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55766 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 60555 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Ishikawa : Site Ref # / Investigator 55162 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Itabashi-ku : Site Ref # / Investigator 48999 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 48647 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 60394 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 55904 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 48649 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 55842 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 55903 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 60538 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 60223 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 60263 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Iwate : Site Ref # / Investigator 60249 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56018 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56019 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56021 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56025 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 55805 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 55782 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 55173 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 48756 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 55716 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56017 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56020 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56022 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 56023 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 60221 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 65129 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagawa : Site Ref # / Investigator 49070 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 49095 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 48777 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 48779 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 65135 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 60517 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 60222 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 56079 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 56070 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 48778 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 49091 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 49092 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 56069 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 56077 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 60377 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kagoshima : Site Ref # / Investigator 65134 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60566 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60415 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60416 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60424 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60542 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60521 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60504 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55801 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55840 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55850 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55852 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55856 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55858 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55864 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55699 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55663 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55324 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 48678 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 48680 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60399 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60518 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60520 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60422 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60506 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 60533 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 65152 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55843 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55802 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55851 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55857 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55859 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55860 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55861 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55862 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55863 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55160 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55187 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55310 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 55571 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 48677 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kanagawa : Site Ref # / Investigator 48679 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 48759 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 55719 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 55657 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 60408 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 60260 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 60264 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 56027 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 56031 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 56034 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 49072 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 55783 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kochi : Site Ref # / Investigator 56033 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60220 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60367 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60427 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60411 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60382 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # /Investigator 60385 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 56071 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 48781 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 48773 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 56065 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 56066 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 56067 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 56068 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60369 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 65141 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 60550 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 48774 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 48775 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 48776 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kumamoto : Site Ref # / Investigator 49094 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kurume : Research Site

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Kyoto : Site Ref # / Investigator 49051 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 49053 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55587 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55577 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 60381 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55718 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55774 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55775 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55776 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55777 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55829 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 49054 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 48745 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 48746 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 48747 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55322 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55828 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55661 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55772 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55773 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 55778 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 65102 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Kyoto : Site Ref # / Investigator 65108 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 65119 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55630 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55632 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55634 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55635 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55636 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 49024 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55631 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55633 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 55637 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Mie : Site Ref # / Investigator 48699 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 48982 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 48651 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 48653 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55175 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55176 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55929 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55930 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55931 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55932 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55917 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 65150 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # /Investigator 60384 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 60561 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 48986 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 48655 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 60379 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55918 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55919 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55942 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 55943 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyagi : Site Ref # / Investigator 68736

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Miyazaki : Site Ref # / Investigator 56055 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyazaki : Site Ref # / Investigator 56060 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyazaki : Site Ref # / Investigator 56061 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyazaki : Site Ref # / Investigator 56063 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Miyazaki : Site Ref # / Investigator 56064 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 60507 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 60564 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55921 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55922 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55923 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55924 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55707 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55708 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 55159 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 48780 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagano : Site Ref # / Investigator 48993 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 48769 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 48770 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 55866 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 56058 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 60266 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 65132 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 65133 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 60545 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 56053 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 60252 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 48782 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 48771 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nagasaki : Site Ref # / Investigator 49082 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55166 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55680 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55681 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55683 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 49043 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55189 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55602 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55679 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55682 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55684 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nara : Site Ref # / Investigator 55685 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Nigata : Site Ref # / Investigator 49025 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48987 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48988 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48985 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55619 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55582 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55954 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55646 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55320 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48989 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48990 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55158 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 48983 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 65112 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55952 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Niigata : Site Ref # / Investigator 55953 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 56059 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 56056 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 56057 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 56054 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 48772 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 49087 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 49088 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 56062 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 60410 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 55607 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 49089 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 49090 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Oita : Site Ref # / Investigator 49093 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55169 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 49055 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 49059 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 60516 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 60527 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55995 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55984 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 49056 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 48748 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 48749 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 60390 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 65127 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 60529 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55988 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55989 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55990 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55991 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okayama : Site Ref # / Investigator 55992 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 60548 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 60255 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56073 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56076 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56080 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56081 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56072 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56074 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56075 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 55702 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 60420 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 60268 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 56078 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 60393 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 65136 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 65137 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 49096 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Okinawa : Site Ref # / Investigator 49097 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Osaka : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Osaka : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Osaka : Site Ref # / Investigator 65104 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 65122 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # /Investigator 60383 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60565 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60544 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60365 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60366 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60421 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60512 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55717 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55668 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55672 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55674 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55675 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55676 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55794 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55165 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55321 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55648 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55649 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55650 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55651 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55653 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55590 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55592 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49027 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49030 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49034 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49035 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49048 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48701 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48703 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48700 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48702 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48704 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48705 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 48706 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49028 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49029 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49031 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49032 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49033 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49036 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 49037 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55578 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55174 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55308 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55652 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55654 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55655 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55656 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55666 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55667 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55669 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55670 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55671 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55673 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55677 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55678 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60243 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60549 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60546 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60539 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 60505 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 65120 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 65121 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55706 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Osaka : Site Ref # / Investigator 55712 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 60503 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56050 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56045 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56046 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56047 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 49085 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56049 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 56051 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saga : Site Ref # / Investigator 60396 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 60534 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 60419 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 65149 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55844 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55845 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55846 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55848 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55834 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55839 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 48673 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 48674 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 48675 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 48676 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 49014 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 49017 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55606 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55323 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 60541 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 60526 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 65118 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 65147 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55855 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55847 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55849 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55833 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55835 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55836 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55837 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Saitama : Site Ref # / Investigator 55838 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Sendai : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shiga : Site Ref # / Investigator 55662 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55664 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55982 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55983 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55986 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 60522 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 60250 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55586 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 49057 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55985 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 55987 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shiga : Site Ref # / Investigator 60409 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 55721 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 65145 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 65128 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 55715 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 49061 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shimane : Site Ref # / Investigator 49062 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55611 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55612 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55613 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55614 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55790 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55881 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 65153 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 60418 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55882 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55883 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 60406 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 60400 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 60374 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 49021 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 49012 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 49009 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55589 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55579 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55609 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55610 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 55317 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 48687 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 48688 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 48689 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 48690 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Shizuoka : Site Ref # / Investigator 48691 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 60562 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 55960 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 55961 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 55962 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 55659 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 60254 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 60265 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tochigi : Site Ref # / Investigator 55830 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 56028 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 56029 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 55580 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 56030 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 56032 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 55314 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokushima : Site Ref # / Investigator 49073 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tokyo : Site Ref # / Investigator 48658 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48661 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48662 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48663 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48664 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55306 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55191 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55318 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55604 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55594 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55595 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55598 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 49004 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 49005 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48992 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48783 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55933 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55934 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55935 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55936 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55937 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55944 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55945 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55695 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55714 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55722 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55792 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55854 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55867 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65103 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65113 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65114 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65142 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65139 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60404 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60425 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60417 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60543 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60532 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60511 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55572 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55575 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55576 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55168 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55170 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55161 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 49044 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48996 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48997 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 49007 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 49003 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48660 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 48665 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60370 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60245 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60247 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60392 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref #/ Investigator 48659 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 65106 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60514 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60536 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 60547 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55799 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55795 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55786 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55787 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55784 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55819 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55711 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55698 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55938 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55939 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55940 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55941 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55925 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55926 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55927 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tokyo : Site Ref # / Investigator 55928 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55998 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55999 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55709 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 48750 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55993 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55994 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55996 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 49058 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Tottori : Site Ref # / Investigator 55658 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 48742 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 48743 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 55760 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 55761 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 55762 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 60405 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 49049 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 55171 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 55309 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 60373 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Toyama : Site Ref # / Investigator 60395 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Urayasu : Site Ref # / Investigator 55167 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 49050 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 49045 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55686 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55687 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55688 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55689 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 60391 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 60551 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 60525 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 65123 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55696 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 60371 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Wakayama : Site Ref # / Investigator 55690 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 55910 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 55911 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 60403 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 60219 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 60267 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 65154 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 55915 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamagata : Site Ref # / Investigator 55916 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56013 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56016 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56009 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 55700 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 55591 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 49060 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 49066 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 49067 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 48755 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 60515 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56015 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56011 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 56012 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 48752 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 48753 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 48754 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamaguchi : Site Ref # / Investigator 49065 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamanashi : Site Ref # / Investigator 55920 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Yamanashi : Site Ref # / Investigator 55969 Updated

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Seoul : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Seoul : Coordinating Location Updated

Post Marketing Surveillance of Remicade (Study P05224)

Kuala Lumpur :

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Alkmaar : Site Reference ID/Investigator# 38181

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Almere : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amersfoort : Site Reference ID/Investigator# 38179

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amsterdam : Site Reference ID/Investigator# 43042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Amsterdam : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Amsterdam Zuidoost : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Leiden : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Leiden : Site Reference ID/Investigator# 38180

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rotterdam : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rotterdam : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Auckland : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Auckland Grafton : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Christchurch : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Christchurch : University of Otago Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Christchurch : University of Otago Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dunedin : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamilton : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamilton : Waikato Hospital Updated

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Hamilton : Waikato Hospital Updated

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Lower Hutt : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Wellington : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Ålesund : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bergen : Department of Medicine, Haukeland University Hospital

Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease

Gjettum : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Norway : Norway

A Study of TRK-170 for the Treatment of Crohn's Disease

Tønsberg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tønsberg : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tromsø : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tromsø : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bydgoszcz : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lodz : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Warszawa : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Warszawa :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Wroclaw : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Wrocław : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Ponce : Pharmaseek, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Ponce : Pharmaseek, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Ekaterinburg : 013

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Kazan : 012

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Kazan : 016

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 014

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 005

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 007

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 008

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 009

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Moscow : 011

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 006

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 003

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 004

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint Petersburg : 001

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Saint-Petersburg :

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Samara : 015

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Shakhty : 017

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Taganrog : 010

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Yaroslavl : 002

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA)

Bratislava : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bratislava : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bellville : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Overport : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Overport : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Barcelona : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Madrid : Site Reference ID/Investigator# 38185

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Madrid : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Majadahonda : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Majadahonda : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Sabadell : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Gothenburg : Site Reference ID/Investigator# 39065

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lund : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Orebro : Site Reference ID/Investigator# 39066

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Stockholm : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Stockholm : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Stockholm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Uppsala : Site Reference ID/Investigator# 39082

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bern : Site Reference ID/Investigator# 38192

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zurich : Novartis Investigative Site

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Zurich :

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Zurich : Site Reference ID/Investigator# 38191

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bristol : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bristol : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bristol : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Cambridge : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Cardiff : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Edinburgh : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edinburgh : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Exeter :

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Harrow : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Headington Oxford : Site Reference ID/Investigator# 38196

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

London : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Manchester : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Newcastle-upon-Tyne : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Norwich : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nottinghamshirecc : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oxford : Updated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oxford : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Oxford : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oxford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Salford : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Salford : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Salford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Worthing : Worthing Hospital

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

Washington : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Washington : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Clinical Trials: Crohn's Disease

Alabama

Arizona

Arkansas

California

Colorado

Connecticut

Florida

Georgia

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Nebraska

Nevada

New Hampshire

New Jersey

New York

North Carolina

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Australia

Austria

Belgium

Brazil

Canada

Czech Republic

Denmark

France

Germany

Greece

Hungary

Iceland

Ireland

Israel

Italy

Japan

Korea, Republic of

Malaysia

Netherlands

New Zealand

Norway

Poland

Puerto Rico

Russian Federation

Slovakia

South Africa

Spain

Sweden

Switzerland

United Kingdom

United States